Moisés Armides Franco-Molina

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2644826/publications.pdf

Version: 2024-02-01

53 papers 807 citations

16 h-index 26 g-index

54 all docs

54 docs citations

54 times ranked

1272 citing authors

#	Article	IF	CITATIONS
1	Bovine Dialyzable Leukocyte Extract IMMUNEPOTENT CRP: Evaluation of Biological Activity of the Modified Product. Applied Sciences (Switzerland), 2021, 11, 3505.	2.5	1
2	Fatal Case of Rabies in a Captive White-Tailed Deer: A Case Report from Chiapas, Mexico. Tropical Medicine and Infectious Disease, 2021, 6, 135.	2.3	4
3	Evaluation of the cytotoxic and immunogenic potential of temozolamide, panobinostat, and extract against C6 glioma cells. EXCLI Journal, 2021, 20, 614-624.	0.7	5
4	The Inflammatory Process Modulates the Expression and Localization of WT1 in Podocytes Leading to Kidney Damage. In Vivo, 2021, 35, 3137-3146.	1.3	8
5	Effects of Transportation Stress on Complete Blood Count, Blood Chemistry, and Cytokine Gene Expression in Heifers. Veterinary Sciences, 2021, 8, 231.	1.7	0
6	In Vivo Evaluation of the Antitumor and Immunogenic Properties of Silver and Sodium Dichloroacetate Combination against Melanoma. Journal of Nanomaterials, 2020, 2020, 1-8.	2.7	3
7	IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model. Biomedicine and Pharmacotherapy, 2020, 126, 110062.	5.6	11
8	Triggering of protease-activated receptors (PARs) induces alternative M2 macrophage polarization with impaired plasticity. Molecular Immunology, 2019, 114, 278-288.	2.2	14
9	Inhibitory Effect of <i> Cuphea aequipetala</i> Extracts on Murine B16F10 Melanoma <i> In Vitro</i> and <i> In Vivo</i> . BioMed Research International, 2019, 2019, 1-11.	1.9	16
10	A Novel Gold Calreticulin Nanocomposite Based on Chitosan for Wound Healing in a Diabetic Mice Model. Nanomaterials, 2019, 9, 75.	4.1	38
11	Advantages of adipose tissue stem cells over CD34+ mobilization to decrease hepatic fibrosis in Wistar rats. Annals of Hepatology, 2019, 18, 620-626.	1.5	12
12	shRNA-WT1 Potentiates Anticancer Effects of Gemcitabine and Cisplatin Against B16F10 Lung Metastases <i>In Vitro</i> i>and <i>In Vivo</i> i>. In Vivo, 2019, 33, 777-785.	1.3	12
13	Chitosan Nanoparticles Plus KLH Adjuvant as an Alternative for Human Dendritic Cell Differentiation. Current Nanoscience, 2019, >15, 532-540.	1.2	2
14	Anti-inflammatory and antimicrobial activity of bioactive hydroxyapatite/silver nanocomposites. Journal of Biomaterials Applications, 2019, 33, 1314-1326.	2.4	18
15	Immunotherapy for the treatment of canine transmissible venereal tumor based in dendritic cells pulsed with tumoral exosomes. Immunopharmacology and Immunotoxicology, 2019, 41, 48-54.	2.4	18
16	Evaluation of a canine transmissible venereal tumour cell line with tumour immunity capacity but without tumorigenic property. Journal of Veterinary Research (Poland), 2019, 63, 225-233.	1.0	6
17	Cytokines profile in immunocompetent mice during Trichosporon asahii infection. Medical Mycology, 2018, 56, 103-109.	0.7	8
18	Autologous canine immunotherapy: short-time generated dendritic cells loaded with canine transmissible venereal tumor-whole lysate. Immunopharmacology and Immunotoxicology, 2018, 40, 437-443.	2.4	1

#	Article	IF	CITATIONS
19	Immunogenic potential of three transmissible venereal tumor cell lysates to prime canine-dendritic cells for cancer immunotherapy. Research in Veterinary Science, 2018, 121, 23-30.	1.9	9
20	Development of a Novel Scaffold of Chitosan, Type IV Collagen and Integrin $\hat{l}\pm3\hat{l}^21$ As Alternative Scaffold for Primary Culture of Podocytes. Applied Sciences (Switzerland), 2018, 8, 930.	2.5	2
21	IMMUNEPOTENT CRP induces cell cycle arrest and caspase-independent regulated cell death in HeLa cells through reactive oxygen species production. BMC Cancer, 2018, 18, 13.	2.6	17
22	Increase of the antitumour efficacy of the biocompound IMMUNEPOTENT CRP by enzymatic treatment. Biotechnology and Biotechnological Equipment, 2018, 32, 1028-1035.	1.3	5
23	Clinical trial evaluating the effectiveness of biocompound IMMUNEPOTENT CRP in the third-molar extraction. Biotechnology and Biotechnological Equipment, 2017, 31, 182-186.	1.3	3
24	The novel immunomodulator IMMUNEPOTENT CRP combined with chemotherapy agent increased the rate of immunogenic cell death and prevented melanoma growth. Oncology Letters, 2017, 14, 844-852.	1.8	17
25	Cytoplasmic Localization of WT1 and Decrease of miRNA-16-1 in Nephrotic Syndrome. BioMed Research International, 2017, 2017, 1-8.	1.9	13
26	ALTERATIONS OF ANTITUMOR AND METABOLIC RESPONSES IN L5178Y-R LYMPHOMA-BEARING MICE AFTER ONLY 30-MINUTE DAILY CHRONIC STRESS EXPOSURE. Experimental Oncology, 2017, 39, 276-280.	0.1	1
27	Silencing of Foxp3 delays the growth of murine melanomas and modifies the tumor immunosuppressive environment. OncoTargets and Therapy, 2016, 9, 243.	2.0	13
28	In Vitro Evaluation of Colloidal Silver on Immune Function: Antilymphoproliferative Activity. Journal of Nanomaterials, 2016, 2016, 1-8.	2.7	3
29	<i>In Vivo</i> Chemoprotective Activity of Bovine Dialyzable Leukocyte Extract in Mouse Bone Marrow Cells against Damage Induced by 5-Fluorouracil. Journal of Immunology Research, 2016, 2016, 1-10.	2.2	19
30	WT1 shRNA delivery using transferrin-conjugated PEG liposomes in an in vivo model of melanoma. Experimental and Therapeutic Medicine, 2016, 12, 3778-3784.	1.8	17
31	Effect of bovine dialyzable leukocyte extract on induction of cell differentiation and death in K562 human chronic myelogenous leukemia cells. Oncology Letters, 2016, 12, 4449-4460.	1.8	5
32	Expression of Foxp3, CD25 and IL-2 in the B16F10 cancer cell line and melanoma is correlated with tumor growth in mice. Oncology Letters, 2013, 6, 1195-1200.	1.8	13
33	WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells. Oncology Letters, 2012, 3, 751-755.	1.8	22
34	CD133 antisense suppresses cancer cell growth and increases sensitivity to cisplatin in vitro. Experimental and Therapeutic Medicine, 2012, 4, 901-905.	1.8	2
35	Anti-inflammatory and antioxidant effects of IMMUNEPOTENT CRP in Lipopolysaccharide (LPS)-stimulated human macrophages. African Journal of Microbiology Research, 2011, 5, .	0.4	4
36	Antiangiogenic and antitumor effects of IMMUNEPOTENT CRP in murine melanoma. Immunopharmacology and Immunotoxicology, 2010, 32, 637-646.	2.4	16

#	Article	IF	Citations
37	Antitumor activity of colloidal silver on MCF-7 human breast cancer cells. Journal of Experimental and Clinical Cancer Research, 2010, 29, 148.	8.6	152
38	Expression of Prostate Apoptosis Response (Par-4) Is Associated with Progesterone Receptor in Breast Cancer. Archives of Medical Research, 2009, 40, 595-599.	3.3	20
39	Production of biologically active human lymphotactin (XCL1) by Lactococcus lactis. Biotechnology Letters, 2009, 31, 215-220.	2.2	7
40	WT1 gene silencing by aerosol delivery of PEI–RNAi complexes inhibits B16-F10 lung metastases growth. Cancer Gene Therapy, 2009, 16, 892-899.	4.6	70
41	Secretion of biologically active interferon-gamma inducible protein-10 (IP-10) by Lactococcus lactis. Microbial Cell Factories, 2008, 7, 22.	4.0	13
42	IMMUNEPOTENT CRP (bovine dialyzable leukocyte extract) adjuvant immunotherapy: a phase I study in non-small cell lung cancer patients. Cytotherapy, 2008, 10, 490-496.	0.7	28
43	Bovine dialyzable leukocyte extract modulates AP-1 DNA-binding activity and nuclear transcription factor expression in MCF-7 breast cancer cells. Cytotherapy, 2008, 10, 212-219.	0.7	14
44	RNAi silencing of the WT1 gene inhibits cell proliferation and induces apoptosis in the B16F10 murine melanoma cell line. Melanoma Research, 2007, 17, 341-348.	1.2	20
45	Bovine dialyzable leukocyte extract modulates cytokines and nitric oxide production in lipopolysaccharide-stimulated human blood cells. Cytotherapy, 2007, 9, 379-385.	0.7	8
46	Adjuvant effects of crystal proteins from a Mexican strain of Bacillus thuringiensis on the mouse humoral response. Biologicals, 2007, 35, 271-276.	1.4	10
47	Spontaneous Inflammatory Cytokine Gene Expression in Normal Human Peripheral Blood Mononuclear Cells. Lymphatic Research and Biology, 2006, 4, 34-40.	1.1	7
48	In vitro effects of bovine dialyzable leukocyte extract (bDLE) in cancer cells. Cytotherapy, 2006, 8, 408-414.	0.7	24
49	In VitroAntibacterial Activity of Bovine Dialyzable Leukocyte Extract. Immunopharmacology and Immunotoxicology, 2006, 28, 471-483.	2.4	8
50	Bovine Dialyzable Leukocyte Extract Modulates the Nitric Oxide and Pro-Inflammatory Cytokine Production in Lipopolysaccharide-Stimulated Murine Peritoneal MacrophagesIn Vitro. Journal of Medicinal Food, 2005, 8, 20-26.	1.5	23
51	Bovine dialyzable leukocyte extract protects against LPS-induced, murine endotoxic shock. International Immunopharmacology, 2004, 4, 1577-1586.	3.8	25
52	In vitroimmunopotentiating properties and tumour cell toxicity induced byLophophora williamsii(peyote) cactus methanolic extract. Phytotherapy Research, 2003, 17, 1076-1081.	5.8	20
53	Air Pouch Model: An Alternative Method for Cancer Drug Discovery. , 0, , .		0